Lewis H. Titterton, Jr. Buys 6,000 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. purchased 6,000 shares of the stock in a transaction on Tuesday, January 21st. The shares were purchased at an average price of $2.59 per share, with a total value of $15,540.00. Following the acquisition, the director now directly owns 928,334 shares in the company, valued at $2,404,385.06. This represents a 0.65 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Anixa Biosciences Trading Down 1.7 %

Shares of NASDAQ:ANIX opened at $2.92 on Friday. The firm has a 50 day simple moving average of $2.76 and a 200-day simple moving average of $3.03. Anixa Biosciences, Inc. has a twelve month low of $2.07 and a twelve month high of $4.94. The company has a market capitalization of $94.02 million, a PE ratio of -7.49 and a beta of 0.90.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings results on Friday, January 10th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. As a group, equities research analysts predict that Anixa Biosciences, Inc. will post -0.46 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on ANIX shares. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a research note on Tuesday, November 19th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a research report on Wednesday.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in shares of Anixa Biosciences during the third quarter worth approximately $34,000. Tyler Stone Wealth Management raised its position in Anixa Biosciences by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after purchasing an additional 21,008 shares during the last quarter. Westside Investment Management Inc. boosted its stake in Anixa Biosciences by 151.8% during the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after purchasing an additional 21,100 shares during the period. Finally, International Assets Investment Management LLC grew its position in Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after purchasing an additional 23,800 shares during the last quarter. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.